Pharmaceutical composition comprises 2 to 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine- 24-dione i. a. rosiglitazone in the form of a free base or a tautomeric form thereof and/or in the form of a pharmaceutically acceptable derivative and a sulphonylurea preferably glibenclamide glipizide gliclazide glimepiride tolazamide or tolbutamide. Also disclosed is the use of 2 to 8 mg of rosiglitazone and a sulphonylurea for the manufacture of a medicament for the treatment of...

A composition comprising a novel Ca2+-activated [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion which causes severe cell depolarization followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited by su...

The present invention is directed to therapeutic compounds, treatment methods, and kits affecting the NCCa-ATP channel of neural tissue, including neurons, glia and blood vessels within the nervous system, and methods of using same. The NCCa-ATP channel is newly expressed in neural tissue following injury such as ischemia, and is regulated by the sulfonylurea receptor SUR1, being inhibited by sulfonylurea compounds, e.g., glibenclamide and tolbutamide, and opened by diazoxide. Antagonists of the...

The present invention is directed to therapeutic compounds treatment methods and kits affecting the NCCa-ATP channel of neural tissue including neurons glia and blood vessels within the nervous system and methods of using same. The NCCa-ATP channel is newly expressed in neural tissue following injury such as ischemia and is regulated by the sulfonylurea receptor SUR1 being inhibited by sulfonylurea compounds e.g. glibenclamide and tolbutamide and opened by diazoxide. Antagonists of the NCCa-ATP ...

A composition comprising a novel Ca<2+>-activated, [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion, which causes severe cell depolarization, followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited...

A composition comprising a novel Ca2+-activated [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion which causes severe cell depolarization followed by cell swelling. The NCCa-ATP channel is regulated by a sulfonylurea receptor and is inhibited by su...

A method is provided for treatment of Parkinson's disease or controlling movement of a Parkinsonian patient by administering an ATP-sensitive potassium channel blocker such as a sulfonyl urea (for example tolbutamide) or quinine.

Diseases Mediated by transglutaminase, such as Huntington's Disease, spinobulbar atrophy, spinocerebellar ataxia, and dentatorubralpallidoluysian atrophy, as well as inflammatory diseases of the central nervous system, including mautiple sclerosis, rheumatoid arthritis, and insulin dependent diabetes mellitus, can be treated by administering a transglutaminase inhibitor such as monadansyl cadaverine, monoamines and diamines such as cystamine, putrescine, GABA. (gamma-amino benzoic acid), N-benzy...

This invention provides methods of using a pharmacological combination of a biguanide agents such as metformin and one or more PTPase inhibiting agents and optionally one or more sulfonlylurea agents including glyburide glyburide glipizide glimepiride chlorpropamide tolbutamide or tolazamide for treatment in a mammal of Syndrome X type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose lev...